The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy

Epilepsia

Volumn 53, Issue 5, 2012, Pages 870-878

  Vermoesen, Katia ^a   Massie, Ann ^a   Smolders, Ilse ^a   Clinckers, Ralph ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Anticonvulsant; Citalopram; Kainic acid; Reboxetine; Temporal lobe epilepsy

Indexed keywords

CITALOPRAM; KAINIC ACID; REBOXETINE;

ARTICLE; CHRONIC DISEASE; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; TEMPORAL LOBE EPILEPSY; VIDEORECORDING;

ANIMALS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; KAINIC ACID; MALE; MORPHOLINES; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STATUS EPILEPTICUS; TIME FACTORS; TREATMENT OUTCOME; VIDEO RECORDING;

EID: 84860687657     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03436.x     Document Type: Article

References (61)

1. Ahern TH, Javors MA, Eagles DA, Martillotti J, Mitchell HA, Liles LC, Weinshenker D,. (2006) The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice. Neuropsychopharmacology 31: 730-738.
2. Alper K, Schwartz KA, Kolts RL, Khan A,. (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62: 345-354.
3. Arunrut T, Alejandre H, Chen M, Cha J, Russo-Neustadt A,. (2009) Differential behavioral and neurochemical effects of exercise, reboxetine and citalopram with the forced swim test. Life Sci 84: 584-589.
4. Bagdy G, Kecskemeti V, Riba P, Jakus R,. (2007) Serotonin and epilepsy. J Neurochem 100: 857-873.
5. Bahremand A, Payandemehr B, Rahimian R, Ziai P, Pourmand N, Loloee S, Ebrahimi A, Ghasemi A, Fakhfouri G, Ghasemi M, Dehpour AR,. (2011) The role of 5-HT(3) receptors in the additive anticonvulsant effects of citalopram and morphine on pentylenetetrazole-induced clonic seizures in mice. Epilepsy Behav 21: 122-127.
6. Barry JJ, Ettinger AB, Friel P, Gilliam FG, Harden CL, Hermann B, Kanner AM, Caplan R, Plioplys S, Salpekar J, Dunn D, Austin J, Jones J,. (2008) Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 13: S1-S29.
7. Brodie MJ, Richens A, Yuen AW,. (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 345: 476-479.
8. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y,. (2004) Anticonvulsant action of GBR-12909 and citalopram against acute experimentally induced limbic seizures. Neuropharmacology 47: 1053-1061.
9. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y,. (2005) Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10- hydroxycarbamazepine. Neurosci Lett 390: 48-53.
10. Clinckers R, Zgavc T, Vermoesen K, Meurs A, Michotte Y, Smolders I,. (2010) Pharmacological and neurochemical characterization of the involvement of hippocampal adrenoreceptor subtypes in the modulation of acute limbic seizures. J Neurochem 115: 1595-1607.
11. Connor TJ, Kelliher P, Harkin A, Kelly JP, Leonard BE,. (1999) Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat. Eur J Pharmacol 379: 125-133.
12. Cotterman-Hart S,. (2010) Depression in epilepsy: why aren't we treating? Epilepsy Behav 19: 419-421.
13. Cramer JA, Blum D, Reed M, Fanning K,; Epilepsy Impact Project Group. (2003) The influence of comorbid depression on seizure severity. Epilepsia 44: 1578-1584.
14. Curran S, de Pauw K,. (1998) Selecting an antidepressant for use in a patient with epilepsy. Safety considerations. Drug Saf 18: 125-133.
15. Dostert P, Benedetti MS, Poggesi I,. (1997) View of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 7 (Suppl. 1): S23-S35; discussion S71-3.
16. Fattore C, Perucca E,. (2011) Novel medications for epilepsy. Drugs 71: 2151-2178.
17. Favale E, Audenino D, Cocito L, Albano C,. (2003) The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 12: 316-318.
18. Giorgi FS, Pizzanelli C, Biagioni F, Murri L, Fornai F,. (2004) The role of norepinephrine in epilepsy: from the bench to the bedside. Neurosci Biobehav Rev 28: 507-524.
19. Glien M, Brandt C, Potschka H, Löscher W,. (2002) Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43: 350-357.
20. Grabenstatter HL, Ferraro DJ, Williams PA, Chapman PL, Dudek FE,. (2005) Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 46: 8-14.
21. Grabenstatter HL, Clark S, Dudek FE,. (2007) Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols. Epilepsia 48: 2287-2295.
22. Harden CL,. (2002) The co-morbidity of depression and epilepsy: epidemiology, etiology, and treatment. Neurology 59: S48-S55.
23. Harkin A, Kelly JP, McNamara M, Connor TJ, Dredge K, Redmond A, Leonard BE,. (1999) Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 364: 123-132.
24. Hellier JL, Patrylo PR, Buckmaster PS, Dudek FE,. (1998) Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy. Epilepsy Res 31: 73-84.
25. Hernandez EJ, Williams PA, Dudek FE,. (2002) Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. Epilepsia 43: 1337-1345.
26. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ,. (2007) Predictors of pharmacoresistant epilepsy. Epilepsy Res 75: 192-196.
27. Hovorka J, Herman E, Nemcová I,. (2000) Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav 1: 444-447.
28. Hyttel J, Overø KF, Arnt J,. (1984) Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology (Berl) 83: 20-27.
29. Jobe PC, Browning RA,. (2005) The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 7: 602-619.
30. Kabuto H, Yokoi I, Takei M, Kurimoto T, Mori A,. (1994) The anticonvulsant effect of citalopram on El mice, and the levels of tryptophan and tyrosine and their metabolites in the brain. Neurochem Res 19: 463-467.
31. Kang S, Kim HJ, Kim HJ, Shin SK, Choi SH, Lee MS, Shin KH,. (2010) Effects of reboxetine and citalopram pretreatment on changes in cocaine and amphetamine regulated transcript (CART) expression in rat brain induced by the forced swimming test. Eur J Pharmacol 647: 110-116.
32. Kanner AM,. (2008) The use of psychotropic drugs in epilepsy: what every neurologist should know. Semin Neurol 28: 379-388.
33. Kanner AM,. (2009) Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin 27: 865-880.
34. Kanner AM,. (2011) Depression and epilepsy: a bidirectional relation? Epilepsia 52: 21-27.
35. Kanner AM, Balabanov A,. (2002) Depression and epilepsy: how closely related are they? Neurology 58: S27-S39.
36. Kondziella D, Asztely F,. (2009) Don't be afraid to treat depression in patients with epilepsy! Acta Neurol Scand 119: 75-80.
37. Kondziella D, Alvestad S, Vaaler A, Sonnewald U,. (2007) Which clinical and experimental data link temporal lobe epilepsy with depression? J Neurochem 103: 2136-2152.
38. Kühn KU, Quednow BB, Thiel M, Falkai P, Maier W, Elger CE,. (2003) Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav 4: 674-679.
39. Kwan P, Sander JW,. (2004) The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 75: 1376-1381.
40. LaFrance WC Jr, Kanner AM, Hermann B,. (2008) Psychiatric comorbidities in epilepsy. Int Rev Neurobiol 83: 347-383.
41. Leite JP, Cavalheiro EA,. (1995) Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 20: 93-104.
42. Löscher W,. (1999) Animal models of epilepsy and epileptic seizures. In, Eadie MJ, Vajda F, (Eds) Antiepileptic drugs: handbook of experimental pharmacology. Springer, Berlin, pp. 19-62.
43. Melzacka M, Rurak A, Adamus A, Daniel W,. (1984) Distribution of citalopram in the blood serum and in the central nervous system of rats after single and multiple dosage. Pol J Pharmacol Pharm 36: 675-682.
44. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, Brocco M,. (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298: 581-591.
45. Nissinen J, Pitkänen A,. (2007) Effect of antiepileptic drugs on spontaneous seizures in epileptic rats. Epilepsy Res 73: 181-191.
46. Noe KH, Locke DE, Sirven JI,. (2011) Treatment of depression in patients with epilepsy. Curr Treat Options Neurol 13: 371-379.
47. Page ME, Brown K, Lucki I,. (2003) Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action. Psychopharmacology (Berl) 165: 194-201.
48. Pineda E, Shin D, Sankar R, Mazarati AM,. (2010) Comorbidity between epilepsy and depression: experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms. Epilepsia 51: 110-114.
49. Pinel JP,. (1983) Effects of diazepam and diphenylhydantoin on elicited and spontaneous seizures in kindled rats: a double dissociation. Pharmacol Biochem Behav 18: 61-63.
50. Preskorn SH,. (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32 (Suppl. 1): 1-21.
51. Preskorn SH, Fast GA,. (1992) Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 53: 160-162.
52. Racine RJ,. (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32: 281-294.
53. Raedt R, Clinckers R, Mollet L, Vonck K, El Tahry R, Wyckhuys T, De Herdt V, Carrette E, Wadman W, Michotte Y, Smolders I, Boon P, Meurs A,. (2011) Increased hippocampal noradrenaline is a biomarker for efficacy of vagus nerve stimulation (VNS) in a limbic seizure model. J Neurochem 117: 461-469.
54. Sánchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O,. (2003) Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167: 353-362.
55. Schmidt D,. (2011) Efficacy of new antiepileptic drugs. Epilepsy Curr 11: 9-11.
56. Specchio LM, Iudice A, Specchio N, La Neve A, Spinelli A, Galli R, Rocchi R, Ulivelli M, de Tommaso M, Pizzanelli C, Murri L,. (2004) Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 27: 133-136.
57. Thapar A, Roland M, Harold G,. (2005) Do depression symptoms predict seizure frequency-or vice versa? J Psychosom Res 59: 269-274.
58. Vermoesen K, Smolders I, Massie A, Michotte Y, Clinckers R,. (2010) The control of kainic acid-induced status epilepticus. Epilepsy Res 90: 164-166.
59. Vermoesen K, Serruys AS, Loyens E, Afrikanova T, Massie A, Schallier A, Michotte Y, Crawford AD, Esguerra CV, de Witte PA, Smolders I, Clinckers R,. (2011) Assessment of the convulsant liability of antidepressants using zebrafish and mouse seizure models. Epilepsy Behav 22: 450-460.
60. Weinshenker D, Szot P,. (2002) The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol Ther 94: 213-233.
61. Williams PA, White AM, Clark S, Ferraro DJ, Swiercz W, Staley KJ, Dudek FE,. (2009) Development of spontaneous recurrent seizures after kainate-induced status epilepticus. J Neurosci 29: 2103-2112.